<DOC>
	<DOCNO>NCT01009203</DOCNO>
	<brief_summary>The primary hypothesis study addition mammalian target rapamycin ( mTOR ) blockade conventional epidermal growth factor receptor ( EGFR ) blockade result synergistic clinical activity Squamous Cell Carcinoma Head Neck ( SCCHN ) , consistent preclinical xenograft data . Patients treated combination temsirolimus erlotinib , previously establish Maximal Tolerated Dose ( MTD ) . The primary signal efficacy progression free survival ( PFS ) , anticipate PFS prolong compare historical PFS SCCHN patient treat erlotinib cetuximab monotherapy .</brief_summary>
	<brief_title>Temsirolimus ( Torisel® ) Erlotinib ( Tarceva® ) Platinum-Refractory/Ineligible , Advanced , Squamous Cell Carcinoma</brief_title>
	<detailed_description>This phase II , multicenter , single arm , open-label study . Thirty-seven patient advance , platinum-refractory platinum-ineligible squamous cell carcinoma head neck sequentially enrol single treatment arm . Patients treat continuous , 28-day cycle 150 mg erlotinib mouth daily 15 mg temsirolimus intervenously weekly . In absence grade 3 high toxicity first cycle , single , intra-patient dose increase 20 mg temsirolimus permit .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Histologically cytologically confirm squamous cell carcinoma head neck , primary site . Nasopharyngeal carcinoma , World Health Organization ( WHO ) Grade I , include . 2 . Advanced disease , fulfil one criterion define : Incurable disease assess surgical radiation oncology Metastatic ( M1 ) disease Persistent progressive disease follow curativeintent radiation , candidate surgical salvage due incurability morbidity 3 . Platinumrefractory platinumineligible , fulfil one criterion define : disease progression 46 cycle platinumcontaining therapy advance set disease progression within 6 month curativeintent treatment , include platinumbased chemotherapy ineligible platinumcontaining therapy , opinion medical oncologist , due medical comorbidities unacceptable risk toxicity patient refuse platinumcontaining therapy 4 . Measurable disease base response evaluation criterion solid tumor ( RECIST ) disease previously irradiate site consider measurable unequivocal progression lesion radiotherapy , lesion contains residual carcinoma biopsy 6 week completion radiotherapy 5 . Easter Cooperative Oncology Group ( ECOG ) performance status 02 time inform consent 6 . Adequate hematologic reserve organ function Absolute neutrophil count &gt; 1200/µl Platelet count &gt; 100,000/µl Renal function : Serum Creatinine ≤ 1.5x upper limit normal ( ULN ) Liver function : Total bilirubin ≤ 1.5x ULN , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5x ULN 7 . Able provide write , voluntary consent 8 . Patients reproductive potential must use effective contraceptive method . 9 . Male female , age ≥ 18 year 10 . Life expectancy ≥ 12 week 1 . Nasopharyngeal primary site , WHO grade II III 2 . Prior treatment block epidermal growth factor receptor ( EGFR ) , advanced disease set 3 . Prior treatment block EGFR curativeintent setting , deliver previous 6 month 4 . Prior treatment drug block mammalian target rapamycin ( mTOR ) 5 . Sensitivity temsirolimus erlotinib 6 . Uncontrolled metastatic disease central nervous system 7 . Radiotherapy within 2 week Cycle 1 ' Day 1 8 . Surgery within 2 week Cycle 1 ' Day 1 9 . Pregnant lactating female 10 . Myocardial infarction ischemia within 6 month precede study treatment 11 . Any co morbid condition ' view attend physician ' render patient high risk treatment complication 12 . No concurrent , investigational antineoplastic agent permit 13 . History prior malignancy within prior five year , exception nonmelanoma carcinoma skin , carcinoma situ cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>head</keyword>
	<keyword>neck</keyword>
	<keyword>aerodigestive</keyword>
</DOC>